
Parkinsons Disease Market
Description
Parkinson’s Disease Market Report and Forecast 2024-2032
The Parkinson’s disease market was valued at USD 5.4 billion in 2023, driven by the increasing geriatric population and growing disease awareness across the 8 major markets. The market is expected to grow at a CAGR of 12.1% during the forecast period 2024-2032, reaching a market value of USD 15 billion by 2032.
Parkinson’s Disease Market Analysis
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It results from the gradual loss of dopamine-producing neurons in the brain, leading to motor symptoms such as tremors, stiffness, and bradykinesia (slowness of movement). Non-motor symptoms, including cognitive decline, depression, and sleep disturbances, also occur. Parkinson’s disease typically affects older adults, with no cure currently available. Treatment focuses on managing symptoms through medications, lifestyle changes, and, in advanced cases, surgical interventions like deep brain stimulation.
Market Drivers
Parkinson’s Disease Market Trends
The Parkinson’s disease market is rapidly evolving, propelled by advancements in drug development and early diagnosis approaches. As ongoing research uncovers new insights into the disease, several significant trends are emerging, shaping the future trajectory of this market.
Parkinson’s Disease Market Segmentation
Market Breakup by Drug Class
Market Breakup by Route of Administration
Market Breakup by End User
Market Breakup by Distribution Channel
Market Breakup by Region
Parkinson’s Disease Market Competitive Landscape
The competitive landscape of the Parkinson’s disease market includes key players such as Teva Pharmaceutical Industries Ltd., Novartis AG, GSK plc, AbbVie Inc, Boehringer Ingelheim International GmbH, H. Lundbeck A/S, UCB S.A., Acadia Pharmaceuticals Inc., Zydus Cadila, and Sun Pharma. These companies are heavily focused on expanding their product portfolios and developing innovative treatments. Strategic collaborations, research partnerships, and ongoing clinical trials are common approaches to strengthen their positions in this growing market.
Key Questions Answered in the Report
The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the Parkinson’s disease market from 2017-2032.
The research report provides the latest information on the market drivers, challenges, and opportunities in Parkinson’s disease.
The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyze the level of competition within the Parkinson’s disease industry and its attractiveness.
The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
The Parkinson’s disease market was valued at USD 5.4 billion in 2023, driven by the increasing geriatric population and growing disease awareness across the 8 major markets. The market is expected to grow at a CAGR of 12.1% during the forecast period 2024-2032, reaching a market value of USD 15 billion by 2032.
Parkinson’s Disease Market Analysis
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It results from the gradual loss of dopamine-producing neurons in the brain, leading to motor symptoms such as tremors, stiffness, and bradykinesia (slowness of movement). Non-motor symptoms, including cognitive decline, depression, and sleep disturbances, also occur. Parkinson’s disease typically affects older adults, with no cure currently available. Treatment focuses on managing symptoms through medications, lifestyle changes, and, in advanced cases, surgical interventions like deep brain stimulation.
Market Drivers
- Increasing Prevalence of Parkinson’s Disease: The rising incidence of Parkinson’s disease, particularly in ageing populations, is a major driver for the market. As life expectancy increases globally, the number of people diagnosed with Parkinson’s is expected to rise significantly, driving the demand for effective treatments.
- Advances in Drug Development: Ongoing research and development efforts are leading to more advanced therapies for Parkinson’s disease, including new formulations of dopamine-based drugs and innovative treatments aimed at slowing disease progression.
- Growing Focus on Early Diagnosis: Advances in diagnostic tools are enabling earlier detection of Parkinson’s disease, allowing for earlier intervention and more effective management of symptoms, thereby increasing the demand for both diagnostic solutions and early-stage treatments.
- Rising Investment in Neurodegenerative Research: Significant investment from government and private sectors into neurodegenerative disease research is accelerating the development of novel treatments and therapies, boosting market growth.
- High Cost of Advanced Therapies: The high cost of cutting-edge treatments, such as dopamine agonists and advanced surgical interventions like deep brain stimulation, limits access for many patients, especially in low-income regions, posing a significant challenge to market growth.
- Side Effects of Current Medications: Many Parkinson’s disease treatments, particularly those involving dopamine replacement, are associated with significant side effects such as dyskinesia, which can complicate long-term management and reduce patient adherence to medication.
- Lack of Disease-Modifying Treatments: While current therapies focus on managing symptoms, there are no disease-modifying treatments that can halt or slow the progression of Parkinson’s. This gap in treatment options presents a major challenge in addressing long-term patient needs.
- Complexity of Disease Progression: Parkinson’s disease progresses differently in each patient, making it challenging to provide consistent treatment approaches. This variability complicates clinical management and requires personalised treatment plans, adding to the complexity of care.
- Development of Neuroprotective Therapies: Research into neuroprotective therapies that could potentially slow or halt the progression of Parkinson’s presents a significant opportunity. These treatments would represent a breakthrough in managing the disease long-term.
- Telemedicine and Remote Monitoring: The rise of telemedicine and wearable technologies provide opportunities for remote patient monitoring and personalised treatment adjustments, enhancing patient care and improving long-term outcomes in Parkinson’s management.
- Focus on Personalised Medicine: Advances in genetic research and biomarker identification are paving the way for personalised treatment approaches in Parkinson’s disease, allowing for more targeted and effective therapies based on individual patient profiles.
Parkinson’s Disease Market Trends
The Parkinson’s disease market is rapidly evolving, propelled by advancements in drug development and early diagnosis approaches. As ongoing research uncovers new insights into the disease, several significant trends are emerging, shaping the future trajectory of this market.
- Growing Use of Dopamine Agonists
- Increased Adoption of Deep Brain Stimulation
- Rising Focus on Non-Motor Symptoms
- Technological Innovations in Drug Delivery
- Increasing Use of Biomarkers for Early Detection:
- Expansion of Clinical Trials for New Therapies:
Parkinson’s Disease Market Segmentation
Market Breakup by Drug Class
- Carbidopa
- Dopamine
- MAO-Inhibitors
- COMT-Inhibitors
- Anticholinergics
- Others
Market Breakup by Route of Administration
- Oral
- Parenteral
- Topical
Market Breakup by End User
- Hospitals
- Homecare Settings
- Specialty Centers
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Independent Pharmacies
- Online Pharmacies
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Parkinson’s Disease Market Competitive Landscape
The competitive landscape of the Parkinson’s disease market includes key players such as Teva Pharmaceutical Industries Ltd., Novartis AG, GSK plc, AbbVie Inc, Boehringer Ingelheim International GmbH, H. Lundbeck A/S, UCB S.A., Acadia Pharmaceuticals Inc., Zydus Cadila, and Sun Pharma. These companies are heavily focused on expanding their product portfolios and developing innovative treatments. Strategic collaborations, research partnerships, and ongoing clinical trials are common approaches to strengthen their positions in this growing market.
Key Questions Answered in the Report
- What factors are driving the growth of the Parkinson’s disease market during the forecast period?
- How are advances in neuroprotective therapies expected to shape the future of Parkinson’s disease treatment?
- What are the key challenges facing patients and healthcare providers in managing Parkinson’s disease?
- How is the adoption of personalised medicine influencing treatment options for Parkinson’s disease?
- What role do emerging markets play in the growth of the Parkinson’s disease market?
- How are technological innovations in drug delivery improving patient outcomes and adherence to Parkinson’s disease treatment?
- What is the impact of telemedicine and remote monitoring on the management of Parkinson’s disease?
- How do different drug classes, such as dopamine and MAO inhibitors, compare in their effectiveness for managing Parkinson’s symptoms?
- What are the major trends driving the adoption of deep brain stimulation in Parkinson’s disease treatment?
- How is the growing focus on non-motor symptoms affecting the development of comprehensive Parkinson’s disease therapies?
- Which regions are expected to see the highest growth in the Parkinson’s disease market, and why?
- What strategic collaborations and partnerships are shaping the competitive landscape of the Parkinson’s disease market?
The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the Parkinson’s disease market from 2017-2032.
The research report provides the latest information on the market drivers, challenges, and opportunities in Parkinson’s disease.
The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyze the level of competition within the Parkinson’s disease industry and its attractiveness.
The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
Table of Contents
250 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Parkinson's Disease Market Overview – 8 Major Markets
- 3.1 Parkinson's Disease Market Historical Value (2017-2023)
- 3.2 Parkinson's Disease Market Forecast Value (2024-2032)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Parkinson's Disease Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Parkinson's Disease Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 U.S.
- 7.1.1.2 United Kingdom
- 7.1.1.3 EU-4
- 7.1.1.4 India
- 7.1.1.5 Japan
- 7.1.2 Diagnosed Cases, by Country
- 7.1.2.1 U.S.
- 7.1.2.2 United Kingdom
- 7.1.2.3 EU-4
- 7.1.2.4 India
- 7.1.2.5 Japan
- 7.1.3 Treatment Seeking Rate, by Country
- 7.1.3.1 U.S.
- 7.1.3.2 United Kingdom
- 7.1.3.3 EU-4
- 7.1.3.4 India
- 7.1.3.5 Japan
- 8 Parkinson's Disease Market Landscape – 8 Major Markets
- 8.1 Parkinson's Disease Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Parkinson's Disease Market: Product Landscape
- 8.2.1 Analysis by Drug Class
- 8.2.2 Analysis by Route of Administration
- 9 Parkinson's Disease Challenges and Unmet Needs
- 9.1 Treatment Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Parkinson's Disease Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Parkinson's Disease Market Segmentation (2018-2034) - 8 Major Markets
- 12.1 Parkinson's Disease Market (2018-2034) by Drug Class
- 12.1.1 Market Overview
- 12.1.2 Carbidopa
- 12.1.3 Dopamine
- 12.1.4 MAO-Inhibitors
- 12.1.5 COMT-Inhibitors
- 12.1.6 Anticholinergics
- 12.1.7 Others
- 12.2 Parkinson's Disease Market (2018-2034) by Route of Administration
- 12.2.1 Market Overview
- 12.2.2 Oral
- 12.2.3 Parenteral
- 12.2.4 Topical
- 12.3 Parkinson's Disease Market (2018-2034) by End User
- 12.3.1 Market Overview
- 12.3.2 Hospitals
- 12.3.3 Homecare Settings
- 12.3.4 Specialty Centers
- 12.3.5 Others
- 12.4 Parkinson's Disease Market (2018-2034) by Distribution Channel
- 12.4.1 Market Overview
- 12.4.2 Hospital Pharmacies
- 12.4.3 Independent Pharmacies
- 12.4.4 Online Pharmacies
- 12.4.5 Others
- 12.5 Parkinson's Disease Market (2018-2034) by Region
- 12.5.1 Market Overview
- 12.5.2 United States
- 12.5.3 EU-4 and the United Kingdom
- 12.5.3.1 Germany
- 12.5.3.2 France
- 12.5.3.3 Italy
- 12.5.3.4 Spain
- 12.5.3.5 United Kingdom
- 12.5.4 India
- 12.5.5 Japan
- 13 United States Parkinson's Disease Market (2018-2034)
- 13.1 United States Parkinson's Disease Market Historical Value (2017-2023)
- 13.2 United States Parkinson's Disease Market Forecast Value (2024-2032)
- 13.3 United States Parkinson's Disease Market (2018-2034) by Drug Class
- 13.3.1 Market Overview
- 13.3.2 Carbidopa
- 13.3.3 Dopamine
- 13.3.4 MAO-Inhibitors
- 13.3.5 COMT-Inhibitors
- 13.3.6 Anticholinergics
- 13.3.7 Others
- 13.4 Parkinson's Disease Market (2018-2034) by Route of Administration
- 13.4.1 Market Overview
- 13.4.2 Oral
- 13.4.3 Parenteral
- 13.4.4 Topical
- 13.4.5 Others
- 13.5 United States Parkinson's Disease Market (2018-2034) by End User
- 13.5.1 Market Overview
- 13.5.2 Hospitals
- 13.5.3 Homecare Settings
- 13.5.4 Specialty Centers
- 13.5.5 Others
- 13.6 United States Parkinson's Disease Market (2018-2034) by Distribution Channel
- 13.6.1 Market Overview
- 13.6.2 Hospital Pharmacies
- 13.6.3 Independent Pharmacies
- 13.6.4 Online Pharmacies
- 13.6.5 Others
- 14 EU-4 and United Kingdom Parkinson's Disease Market (2018-2034)
- 14.1 EU-4 and United Kingdom Parkinson's Disease Market Historical Value (2017-2023)
- 14.2 EU-4 and United Kingdom Parkinson's Disease Market Forecast Value (2024-2032)
- 14.3 EU-4 and United Kingdom Parkinson's Disease Market (2018-2034) by Drug Class
- 14.3.1 Market Overview
- 14.3.2 Carbidopa
- 14.3.3 Dopamine
- 14.3.4 MAO-Inhibitors
- 14.3.5 COMT-Inhibitors
- 14.3.6 Anticholinergics
- 14.3.7 Others
- 14.4 Parkinson's Disease Market (2018-2034) by Route of Administration
- 14.4.1 Market Overview
- 14.4.2 Oral
- 14.4.3 Parenteral
- 14.4.4 Topical
- 14.4.5 Others
- 14.5 EU-4 and United Kingdom Parkinson's Disease Market (2018-2034) by End User
- 14.5.1 Market Overview
- 14.5.2 Hospitals
- 14.5.3 Homecare Settings
- 14.5.4 Specialty Centers
- 14.5.5 Others
- 14.6 EU-4 and United Kingdom Parkinson's Disease Market (2018-2034) by Distribution Channel
- 14.6.1 Market Overview
- 14.6.2 Hospital Pharmacies
- 14.6.3 Independent Pharmacies
- 14.6.4 Online Pharmacies
- 14.6.5 Others
- 15 India Parkinson's Disease Market
- 15.1 India Parkinson's Disease Market Historical Value (2017-2023)
- 15.2 India Parkinson's Disease Market Forecast Value (2024-2032)
- 15.3 India Parkinson's Disease Market (2018-2034) by Drug Class
- 15.3.1 Market Overview
- 15.3.2 Carbidopa
- 15.3.3 Dopamine
- 15.3.4 MAO-Inhibitors
- 15.3.5 COMT-Inhibitors
- 15.3.6 Anticholinergics
- 15.3.7 Others
- 15.4 Parkinson's Disease Market (2018-2034) by Route of Administration
- 15.4.1 Market Overview
- 15.4.2 Oral
- 15.4.3 Parenteral
- 15.4.4 Topical
- 15.4.5 Others
- 15.5 India Parkinson's Disease Market (2018-2034) by End User
- 15.5.1 Market Overview
- 15.5.2 Hospitals
- 15.5.3 Homecare Settings
- 15.5.4 Specialty Centers
- 15.5.5 Others
- 15.6 India Parkinson's Disease Market (2018-2034) by Distribution Channel
- 15.6.1 Market Overview
- 15.6.2 Hospital Pharmacies
- 15.6.3 Independent Pharmacies
- 15.6.4 Online Pharmacies
- 15.6.5 Others
- 16 Japan Parkinson's Disease Market
- 16.1 Japan Parkinson's Disease Market Historical Value (2017-2023)
- 16.2 Japan Parkinson's Disease Market Forecast Value (2024-2032)
- 16.3 Japan Parkinson's Disease Market (2018-2034) by Drug Class
- 16.3.1 Market Overview
- 16.3.2 Carbidopa
- 16.3.3 Dopamine
- 16.3.4 MAO-Inhibitors
- 16.3.5 COMT-Inhibitors
- 16.3.6 Anticholinergics
- 16.3.7 Others
- 16.4 Parkinson's Disease Market (2018-2034) by Route of Administration
- 16.4.1 Market Overview
- 16.4.2 Oral
- 16.4.3 Parenteral
- 16.4.4 Topical
- 16.4.5 Others
- 16.5 Japan Parkinson's Disease Market (2018-2034) by End User
- 16.5.1 Market Overview
- 16.5.2 Hospitals
- 16.5.3 Homecare Settings
- 16.5.4 Specialty Centers
- 16.5.5 Others
- 16.6 Japan Parkinson's Disease Market (2018-2034) by Distribution Channel
- 16.6.1 Market Overview
- 16.6.2 Hospital Pharmacies
- 16.6.3 Independent Pharmacies
- 16.6.4 Online Pharmacies
- 16.6.5 Others
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.2 US FDA
- 17.3 EU EMA
- 17.4 India CDSCO
- 17.5 Japan PMDA
- 18 Patent Analysis
- 18.1 Analysis by Drug Class of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 18.7 Analysis by Key Players
- 19 Clinical Trials Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Grants Analysis
- 20.1 Analysis by Year
- 20.2 Analysis by Amount Awarded
- 20.3 Analysis by Issuing Authority
- 20.4 Analysis by Grant Distribution Channel
- 20.5 Analysis by Funding Institute
- 20.6 Analysis by NIH Departments
- 20.7 Analysis by Recipient Organization
- 21 Funding and Investment Analysis
- 21.1 Analysis by Funding Instances
- 21.2 Analysis by Drug Class of Funding
- 21.3 Analysis by Funding Amount
- 21.4 Analysis by Leading Players
- 21.5 Analysis by Leading Investors
- 21.6 Analysis by Geography
- 22 Strategic Initiatives
- 22.1 Analysis by Partnership Instances
- 22.2 Analysis by Drug Class of Partnership
- 22.3 Analysis by Leading Players
- 22.4 Analysis by Geography
- 23 Supplier Landscape
- 23.1 Market Share by Top 5 Companies
- 23.2 Teva Pharmaceutical Industries Ltd.
- 23.2.1 Financial Analysis
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Company News and Development
- 23.2.5 Certifications
- 23.3 Novartis AG
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Company News and Development
- 23.3.5 Certifications
- 23.4 GSK plc
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Company News and Development
- 23.4.5 Certifications
- 23.5 AbbVie Inc
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Company News and Development
- 23.5.5 Certifications
- 23.6 Boehringer Ingelheim International GmbH
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Company News and Development
- 23.6.5 Certifications
- 23.7 H. Lundbeck A/S
- 23.7.1 Financial Analysis
- 23.7.2 Product Portfolio
- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Company News and Development
- 23.7.5 Certifications
- 23.8 UCB S.A.
- 23.8.1 Financial Analysis
- 23.8.2 Product Portfolio
- 23.8.3 Demographic Reach and Achievements
- 23.8.4 Company News and Development
- 23.8.5 Certifications
- 23.9 Acadia Pharmaceuticals Inc.
- 23.9.1 Financial Analysis
- 23.9.2 Product Portfolio
- 23.9.3 Demographic Reach and Achievements
- 23.9.4 Company News and Development
- 23.9.5 Certifications
- 23.10 Zydus Cadilla
- 23.10.1 Financial Analysis
- 23.10.2 Product Portfolio
- 23.10.3 Demographic Reach and Achievements
- 23.10.4 Company News and Development
- 23.10.5 Certifications
- 23.11 Sun Pharma
- 23.11.1 Financial Analysis
- 23.11.2 Product Portfolio
- 23.11.3 Demographic Reach and Achievements
- 23.11.4 Company News and Development
- 23.11.5 Certifications
- 24 Parkinson's Disease Treatment Drugs - Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Payment Methods (Additional Insight)
- 26.1 Government Funded
- 26.2 Private Insurance
- 26.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
- *The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.